Cost-effectiveness of iodixanol in patients at high risk of contrast-induced nephropathy

Nephrotoxicity of low-osmolality versus iso-osmolality contrast agents: Impact of N-acetylcysteine

“…Iodixanol is more expensive than low-osmolality contrast agents. As recently suggested, this increased cost may be offset by the reduced cost of managing adverse reactions [19]. However, we did not observe any significant difference in the rate of CAN between the iodixanol and iobitridol groups.…”

“…Iodixanol (an iso-osmolality contrast agent) seems to be less nephrotoxic than low-osmolality contrast agents [18]. It has therefore been suggested that, although more expensive, use of iodixanol is cost-effective because the extra cost may be offset by the reduced cost of managing adverse reactions [19]. However, studies comparing isoversus low-osmolality contrast agents were conducted using hydration as the only prophylactic strategy to prevent CAN.…”

Renal Toxicity Evaluation and Comparison Between Visipaque (Iodixanol) and Hexabrix (Ioxaglate) in Patients With Renal Insufficiency Undergoing Coronary Angiography

“…With the aging population and the incidence of diabetes increasing, older and sicker patients with serious renal and cardiovascular comorbidities now comprise a large proportion of those undergoing coronary angiography. Given this trend, the apparent clinical benefit shown for iodixanol versus ioxaglate here has important implications not only in terms of the potential for improved patient outcomes but also in terms of the potential for reduced health care costs in populations that traditionally have been associated with longer hospital stays and greater use of health care resources (25,26).…”

Costo-efectividad de medios de contraste isoosmolales e hiposmolales en pacientes con alto riesgo de nefropatía inducida por medio de contraste

“…An economic analysis conducted for 17 European hospitals showed that Iodixanol appeared to be cost-effective when compared with Iohexol in diabetic patients with renal impairment undergoing angiography (21), although this study measured effectiveness in terms of adverse drug reactions avoided. No previous studies of the costeffectiveness of contrast media in the prevention of CIN in a developing country setting were found in a the review of the literature.…”